# Study to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic Ulcer

> **NCT04784910** · PHASE3 · COMPLETED · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 423 (actual)

## Conditions studied

- Peptic Ulcer

## Interventions

- **DRUG:** DWP14012 20mg
- **DRUG:** Lansoprazole 15 mg
- **DRUG:** DWP14012 20mg placebo
- **DRUG:** Lansoprazole 15 mg placebo

## Key facts

- **NCT ID:** NCT04784910
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-21
- **Primary completion:** 2023-11-27
- **Final completion:** 2023-12-11
- **Target enrollment:** 423 (ACTUAL)
- **Last updated:** 2024-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04784910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04784910, "Study to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic Ulcer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04784910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*